Robert Biesen

List of Publications by Year
in descending order

46 papers	1,647 citations	331670 21 h-index	315739 38 g-index
53 all docs	53 docs citations	53 times ranked	2320 citing authors

#	Article	IF	Citations
1	Choose wisely: imaging for diagnosis of axial spondyloarthritis. Annals of the Rheumatic Diseases, 2022, 81, 237-242.	0.9	38
2	Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus. Rheumatology, 2022, 61, 3396-3400.	1.9	5
3	SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. RMD Open, 2022, 8, e001934.	3.8	16
4	Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 881-888.	0.9	33
5	Contrast-enhanced CT techniques and MRI perform equally well in arthritis imaging of the hand: a prospective diagnostic accuracy study. European Radiology, 2022, 32, 6376-6383.	4.5	3
6	Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Annals of the Rheumatic Diseases, 2022, 81, 1313-1322.	0.9	25
7	Nuclear antigen–reactive CD4+ T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys. Kidney International, 2021, 99, 238-246.	5.2	26
8	Perfusion in hand arthritis on dynamic contrast-enhanced computed tomography: a randomized prospective study using MRI as a standard of reference. Skeletal Radiology, 2021, 50, 59-68.	2.0	7
9	Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE. International Journal of Molecular Sciences, 2021, 22, 2424.	4.1	20
10	CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity. Infection, 2021, 49, 757-762.	4.7	47
11	Quantification of morning stiffness to assess disease activity and treatment effects in rheumatoid arthritis. Rheumatology, 2021, 60, 5282-5291.	1.9	2
12	SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients. Scientific Reports, 2021, 11, 10299.	3.3	14
13	Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response. Annals of the Rheumatic Diseases, 2021, 80, 1361-1362.	0.9	21
14	Granulomatous large vessel phlebitis in sarcoidosis. Rheumatology, 2021, 60, e432-e434.	1.9	0
15	SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus. Lupus, 2020, 29, 1914-1925.	1.6	20
16	Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. New England Journal of Medicine, 2020, 383, 1149-1155.	27.0	178
17	FRI0433â€…EFFECTS OF DISEASE MODIFYING DRUGS ON BONE MINERAL DENSITY, FRACTURE INCIDENCE, BACK PAIN AND PHYSICAL ACTIVITY IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS. , 2019, , .		0
18	Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 31-35.	0.9	14

#	Article	IF	Citations
19	Ultra-Low-Dose Computed Tomography Subtraction for the Detection of Synovitis in Patients with Inflammatory Joint Disease. Seminars in Musculoskeletal Radiology, 2019, 23, .	0.7	0
20	Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. European Journal of Immunology, 2018, 48, 1573-1579.	2.9	57
21	Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. Arthritis Research and Therapy, 2018, 20, 52.	3.5	44
22	Observational study and brief analysis of diagnostic criteria in relapsing polychondritis. Rheumatology International, 2018, 38, 2095-2101.	3.0	12
23	Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options. Journal of Molecular Medicine, 2017, 95, 753-765.	3.9	19
24	Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology, 2017, 56, 1618-1626.	1.9	49
25	Mapping urinary chemokines in human lupus nephritis: Potentially redundant pathways recruit CD4$^+$ and CD8$^+$ T cells and macrophages. European Journal of Immunology, 2017, 47, 180-192.	2.9	26
26	What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. Clinical and Experimental Rheumatology, 2017, 35, 598-606.	0.8	18
27	SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome. RMD Open, 2016, 2, e000292.	3.8	42
28	Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE. Lupus, 2016, 25, 823-829.	1.6	18
29	Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies. Clinical and Experimental Immunology, 2016, 183, 326-340.	2.6	18
30	Siglec-1-positive plasmacytoid dendritic cells (pDCs) in human peripheral blood: A semi-mature and myeloid-like subset imbalanced during protective and autoimmune responses. Clinical Immunology, 2016, 163, 42-51.	3.2	16
31	The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers. Arthritis Research and Therapy, 2015, 17, 94.	3.5	48
32	The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity. Journal of Experimental Medicine, 2014, 211, 427-440.	8.5	51
33	Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Annals of the Rheumatic Diseases, 2014, 73, 277-283.	0.9	60
34	A8.16â€¦T helper lymphocytes and monocytes as biosensors of type I interferon responses in viral infection and autoimmunity. Annals of the Rheumatic Diseases, 2014, 73, A82.2-A82.	0.9	0
35	IFNÎ± and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2013, 72, 1639-1645.	0.9	115
36	A2.6â€¦Cell-Specific Type I IFN Signatures in Autoimmunity and Viral Infection: What Makes the Difference?. Annals of the Rheumatic Diseases, 2013, 72, A6.1-A6.	0.9	0

#	Article	IF	Citations
37	Cell-Specific Type I IFN Signatures in Autoimmunity and Viral Infection: What Makes the Difference?. PLoS ONE, 2013, 8, e83776.	2.5	82
38	Defining T helper (CD4) cell-specific disease signatures in active, inactive and autologous stem cell transplanted lupus patients by global gene expression profiling. Annals of the Rheumatic Diseases, 2012, 71, A51.2-A52.	0.9	0
39	The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. Journal of Molecular Medicine, 2012, 90, 1295-1309.	3.9	67
40	Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus. Arthritis Research and Therapy, 2011, 13, R20.	3.5	16
41	Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthritis Research and Therapy, 2011, 13, R26.	3.5	33
42	The type 1 interferon signature: facts, fads and fallacies. Annals of the Rheumatic Diseases, 2011, 70, A24-A24.	0.9	2
43	Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function. Annals of the Rheumatic Diseases, 2010, 69, 1370-1377.	0.9	48
44	CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis and Rheumatism, 2009, 60, 199-206.	6.7	137
45	From transcriptome to cytome: Integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseases. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 333-340.	1.5	28
46	Sialic acid–binding Ig–like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 58, 1136-1145.	6.7	163